{"id":"interferon-alfa-and-cci-779","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperlipidemia"}]},"_chembl":{"chemblId":"CHEMBL2108506","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alfa is a cytokine that activates natural killer cells and macrophages to enhance anti-tumor immunity. CCI-779 is an mTOR inhibitor that blocks protein synthesis and cell cycle progression in cancer cells. The combination aims to synergize immune activation with direct anti-proliferative effects against tumor cells.","oneSentence":"This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:25.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Renal cell carcinoma"},{"name":"Other advanced malignancies (phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT00631371","phase":"PHASE3","title":"Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Renal Cell Carcinoma","enrollment":791},{"nctId":"NCT00045370","phase":"PHASE1","title":"Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-04","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT00619268","phase":"PHASE2","title":"Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2008-02","conditions":"Metastatic Renal Cell Carcinoma","enrollment":160},{"nctId":"NCT00065468","phase":"PHASE3","title":"Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-07","conditions":"Carcinoma, Renal Cell, Kidney Neoplasms","enrollment":626}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Interferon Alfa and CCI-779","genericName":"Interferon Alfa and CCI-779","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis. Used for Renal cell carcinoma, Other advanced malignancies (phase 3 investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}